The results indicated that blockage of Ago2/CAV1 interaction in A549 cancer cells with P2 peptides decreased cell viability under paclitaxel (Pac) and gefitinib (Gef) treatment, thereby attenuating drug resistance (Fig. 4C). Here, AGO2 is linked to cancer.